New single-use mixing system offers rapid and homogenous mixing
ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.
High Purity New England, a leading supplier of biotech equipment and process systems for the biotech industry, has launched ClearMixx, an innovative single-use mixing system.
The latest addition to the growing High Purity New England product range, ClearMixx, utilizes a low sheer single-use Quattroflow pump chamber and unique cuboidal shaped bag, to provide mixing efficiency and allow the user to create a uniform, completely homogenous mixture.
Mark Sitcoske, CEO and founder at High Purity New England, said: “We developed ClearMixx to meet the growing demand for a more accurate, single-use mixing system. Clearmixx, unlike its competitors, offers rapid and completely homogenous mixing for your process – without any impellers or moving components.”
ClearMixx was designed to perform liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients with scalability from 50 L, 200 L, and 500 L as standard sizes. ClearMixx is offered in both stainless steel or polypropylene skids for flexibility in biomanufacturing.
The launch of the ClearMixx system comes as High Purity New England has recently expanded into its second US manufacturing facility and office space in the Northeast. In the first half of 2020, the company expects to launch at least two other exciting product lines.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...